Published in Cancer Cell on April 13, 2010
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell (2012) 2.18
Malignant pirates of the immune system. Nat Immunol (2011) 1.87
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
Computational methods in drug discovery. Pharmacol Rev (2013) 1.51
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood (2013) 1.48
Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem (2013) 1.46
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med (2011) 1.45
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell (2016) 1.44
STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget (2013) 1.35
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov (2012) 1.33
Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat Immunol (2013) 1.30
A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep (2013) 1.28
Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med (2014) 1.18
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol (2013) 1.17
Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood (2013) 1.15
The genetic basis of diffuse large B-cell lymphoma. Curr Opin Hematol (2013) 1.12
Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol (2011) 1.07
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene (2014) 1.05
Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med (2015) 1.04
KAP1 promotes proliferation and metastatic progression of breast cancer cells. Cancer Res (2014) 0.99
Epigenetics and B-cell lymphoma. Curr Opin Hematol (2011) 0.98
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97
Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene (2013) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion. ACS Chem Biol (2011) 0.94
NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells. Cancer Res (2012) 0.93
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol (2013) 0.93
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood (2012) 0.92
New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Curr Opin Immunol (2013) 0.91
Site-Identification by Ligand Competitive Saturation (SILCS) assisted pharmacophore modeling. J Comput Aided Mol Des (2014) 0.89
T Follicular Helper Cell Plasticity Shapes Pathogenic T Helper 2 Cell-Mediated Immunity to Inhaled House Dust Mite. Immunity (2016) 0.88
Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. BMC Cancer (2011) 0.88
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica (2012) 0.87
K63-linked ubiquitination in kinase activation and cancer. Front Oncol (2012) 0.87
Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res (2014) 0.87
B-cell lymphoma 6 promotes proliferation and survival of trophoblastic cells. Cell Cycle (2016) 0.87
Targeting Transcription Factors in Cancer. Trends Cancer (2015) 0.86
Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications. Cancers (Basel) (2015) 0.86
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest (2016) 0.86
BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends Immunol (2013) 0.85
Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6. Toxicol Sci (2014) 0.83
Pharmacophore modeling using site-identification by ligand competitive saturation (SILCS) with multiple probe molecules. J Chem Inf Model (2015) 0.83
JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev (2015) 0.82
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxid Redox Signal (2014) 0.82
BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer. Am J Cancer Res (2014) 0.81
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol (2013) 0.81
Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol (2013) 0.81
Recent progress in targeting cancer. Aging (Albany NY) (2011) 0.80
Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme. PLoS One (2012) 0.80
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget (2016) 0.79
Small Molecule Inhibitors of Ca(2+)-S100B Reveal Two Protein Conformations. J Med Chem (2016) 0.79
The molecular biology of diffuse large B-cell lymphoma. Ther Adv Hematol (2011) 0.79
The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain. PLoS One (2014) 0.78
The epigenetic basis of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.78
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica (2016) 0.77
Ex vivo engineered immune organoids for controlled germinal center reactions. Biomaterials (2015) 0.77
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer (2015) 0.77
Investigational Notch and Hedgehog inhibitors--therapies for cardiovascular disease. Expert Opin Investig Drugs (2011) 0.77
Novel therapeutic targets in diffuse large B-cell lymphoma. EJC Suppl (2013) 0.77
Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma. Cancer Cell (2010) 0.76
BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy. Oncotarget (2016) 0.76
The next new target in leukemia: The embryonic stem cell gene SALL4. Mol Cell Oncol (2015) 0.76
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials (2015) 0.76
Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL. Leuk Lymphoma (2016) 0.75
Targeting primary mediastinal B-cell lymphoma. Oncotarget (2014) 0.75
The expanding role of the BCL6 oncoprotein as a cancer therapeutic target. Clin Cancer Res (2016) 0.75
Regulation of hematopoietic development by ZBTB transcription factors. Int J Hematol (2016) 0.75
Double-punching PMBL. Oncotarget (2014) 0.75
Kruppel-like Factor 6 Promotes Macrophage-mediated Inflammation by Suppressing B Cell Leukemia/Lymphoma 6 Expression. J Biol Chem (2016) 0.75
Snapshots of CD4(+) T cell plasticity in the pathogenesis of allergic asthma. J Thorac Dis (2016) 0.75
Structures of heterodimeric POZ domains of Miz1/BCL6 and Miz1/NAC1. Acta Crystallogr F Struct Biol Commun (2014) 0.75
Transcriptional repressors, corepressors and chromatin modifying enzymes in T cell development. Cytokine (2010) 0.75
Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. J Biol Chem (2016) 0.75
Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4. Proc Natl Acad Sci U S A (2016) 0.75
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood (2016) 0.75
Bcl6 Sets a Threshold for Antiviral Signaling by Restraining IRF7 Transcriptional Program. Sci Rep (2016) 0.75
Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma. Oncotarget (2015) 0.75
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. Cell Cycle (2016) 0.75
BCL6 promotes glioma and serves as a therapeutic target. Proc Natl Acad Sci U S A (2017) 0.75
Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Sci (2016) 0.75
Inhibition of the transcriptional repressor complex Bcl-6/BCoR induces endothelial sprouting but does not promote tumor growth. Oncotarget (2016) 0.75
An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog (2017) 0.75
BCL6 Overexpression Alters Gene Expression Profile in a Myeloma Cell Line and Is Associated with Decreased DNA Damage Response. Cancer Sci (2017) 0.75
Double-Hit Large B Cell Lymphoma. Curr Oncol Rep (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B (1998) 54.00
HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr (2006) 13.29
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods (2001) 7.08
Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science (1997) 6.58
A geometric approach to macromolecule-ligand interactions. J Mol Biol (1982) 5.71
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature (2004) 5.06
DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des (2001) 4.54
Sequence and structural analysis of BTB domain proteins. Genome Biol (2005) 3.88
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol (2005) 3.75
Structure-based strategies for drug design and discovery. Science (1992) 3.72
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21
MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell (2004) 3.12
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell (2003) 2.20
Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem (2002) 2.10
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A (2007) 2.06
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood (2007) 1.72
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol (2009) 1.60
Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Mol Cell (2008) 1.46
Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother (2009) 1.44
CtBP is an essential corepressor for BCL6 autoregulation. Mol Cell Biol (2008) 1.41
Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J Med Chem (2004) 1.41
Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol (2004) 1.38
Consideration of molecular weight during compound selection in virtual target-based database screening. J Chem Inf Comput Sci (2003) 1.37
Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J Med Chem (2005) 1.25
BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Mol Dis (2008) 1.21
Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther (2000) 1.16
Computational identification of inhibitors of protein-protein interactions. Curr Top Med Chem (2007) 1.14
Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Res (2008) 1.09
Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. Antimicrob Agents Chemother (1993) 1.08
Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site. J Med Chem (2004) 1.07
Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother (1994) 1.04
BCL-6 in the pathogenesis of non-Hodgkin's lymphoma. Cancer Invest (2000) 1.01
Crystal structure of the BTB domain from the LRF/ZBTB7 transcriptional regulator. Protein Sci (2006) 1.01
Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era. Mol Interv (2001) 0.96
Anatomy of fingerprint search calculations on structurally diverse sets of active compounds. J Chem Inf Model (2005) 0.93
Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. J Nucl Med (2005) 0.90
Reprogramming specific gene expression pathways in B-cell lymphomas. Cell Cycle (2005) 0.85
Improving the design and analysis of high-throughput screening technology comparison experiments using statistical modeling. J Biomol Screen (2005) 0.81
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science (2008) 8.04
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature (2009) 6.85
Consistent blind protein structure generation from NMR chemical shift data. Proc Natl Acad Sci U S A (2008) 6.76
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. J Chem Theory Comput (2012) 5.57
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol (2011) 4.77
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41
Sox2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell (2011) 4.29
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Sequence and structural analysis of BTB domain proteins. Genome Biol (2005) 3.88
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol (2011) 3.60
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol (2012) 3.44
Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature (2008) 3.39
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Additive empirical force field for hexopyranose monosaccharides. J Comput Chem (2008) 3.23
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
CHARMM fluctuating charge force field for proteins: II protein/solvent properties from molecular dynamics simulations using a nonadditive electrostatic model. J Comput Chem (2004) 2.79
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
CHARMM Additive All-Atom Force Field for Glycosidic Linkages between Hexopyranoses. J Chem Theory Comput (2009) 2.61
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A (2005) 2.59
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood (2012) 2.55
CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res (2007) 2.48
Structural biology of human H3K9 methyltransferases. PLoS One (2010) 2.45
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Solution structure and dynamics of the outer membrane enzyme PagP by NMR. Proc Natl Acad Sci U S A (2002) 2.39
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A (2009) 2.35
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med (2009) 2.27
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell (2003) 2.20
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell (2012) 2.18
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood (2010) 2.15
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem (2008) 2.12
L3MBTL1 recognition of mono- and dimethylated histones. Nat Struct Mol Biol (2007) 2.12
Genome-wide analysis of substrate specificities of the Escherichia coli haloacid dehalogenase-like phosphatase family. J Biol Chem (2006) 2.10
NMR data collection and analysis protocol for high-throughput protein structure determination. Proc Natl Acad Sci U S A (2005) 2.09
Structural basis for molecular recognition and presentation of histone H3 by WDR5. EMBO J (2006) 2.08
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A (2007) 2.06
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature (2013) 2.04
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood (2009) 2.04
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res (2003) 2.04
Induction of sarcomas by mutant IDH2. Genes Dev (2013) 2.02
Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol (2006) 1.97
SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol (2011) 1.95
An NMR approach to structural proteomics. Proc Natl Acad Sci U S A (2002) 1.95
Optimization of the CHARMM additive force field for DNA: Improved treatment of the BI/BII conformational equilibrium. J Chem Theory Comput (2012) 1.93
Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology (2011) 1.93
Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem (2009) 1.92
Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell (2005) 1.92
Genome-wide chromatin interactions of the Nanog locus in pluripotency, differentiation, and reprogramming. Cell Stem Cell (2013) 1.91
Structural and chemical profiling of the human cytosolic sulfotransferases. PLoS Biol (2007) 1.90
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol (2013) 1.89
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood (2010) 1.87
Polarizable empirical force field for the primary and secondary alcohol series based on the classical Drude model. J Chem Theory Comput (2007) 1.86
Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep (2012) 1.84
Impact of 2'-hydroxyl sampling on the conformational properties of RNA: update of the CHARMM all-atom additive force field for RNA. J Comput Chem (2011) 1.81
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res (2009) 1.80
Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein. J Biol Chem (2011) 1.79
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med (2013) 1.79
Inhibition of neural crest migration underlies craniofacial dysmorphology and Hirschsprung's disease in Bardet-Biedl syndrome. Proc Natl Acad Sci U S A (2008) 1.78
Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. Nat Struct Mol Biol (2012) 1.77
Polarizable empirical force field for aromatic compounds based on the classical drude oscillator. J Phys Chem B (2007) 1.77
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood (2010) 1.77
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS One (2008) 1.76
Recognition and specificity determinants of the human cbx chromodomains. J Biol Chem (2010) 1.76
Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. Brain (2010) 1.76
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood (2009) 1.75
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem (2010) 1.73
Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol (2013) 1.72
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood (2007) 1.72